Nanoparticle embedded dot matrix transdermal patches: a novel approach for targeted and controlled drug delivery in rheumatoid arthritis.

backgroundRA is a chronic autoimmune disease characterized by synovial inflammation, cartilage destruction, and ultimately bone erosion that affects approximately 0.5-1% of the global population, with significant disability. Conventional therapies comprising NSAIDs, corticosteroids, and DMARDs frequently demonstrate systemic toxicity, gastrointestinal complications, and poor patient compliance. This manuscript discusses the role of nanoparticle-based dot-matrix transdermal drug delivery systems as a novel, non-invasive strategy for enhancing targeted, controlled, and localized drug delivery in the management of RA.

methodsThe current literature on RA pathophysiology, existing pharmacological treatments, routes of administration, and the evolution of nanotechnology is integrated into the manuscript. Special attention is paid to nanoparticles based on chitosan due to their biocompatibility, biodegradability, and penetration-enhancing properties, and they were incorporated into dot matrix patch technology fitted with micro-depots for optimized skin permeation, sustained release, and reduced skin irritation.

resultsTraditional transdermal systems exhibit limitations in permeation through the stratum corneum, particularly for hydrophilic or high-molecular-weight substances. Incorporation of nanoparticles (size < 200 nm) improves solubility, stability, shelf life, bioavailability, and enables targeted delivery of therapeutic agents into arthritic joints. This approach facilitates rapid onset of action followed by sustained and controlled drug release, allows individualized dosing, reduces skin irritation, and enhances patient compliance. Importantly, nanoparticle-mediated transdermal systems can effectively deliver conventional drugs such as methotrexate, NSAIDs, and herbal anti-inflammatory agents, as well as disease-modifying antirheumatic drugs (DMARDs), including both conventional synthetic DMARDs and targeted synthetic agents. Additionally, this strategy bypasses first-pass hepatic metabolism, thereby improving systemic availability while potentially reducing systemic adverse effects.

conclusionsThe dot-matrix nanoscale transdermal drug delivery platform has great potential for treating RA, offering controlled, localized drug delivery with improved efficacy and reduced toxicity. In addition to the difficulties with scalability and commercial availability, the technology also requires further studies of its long-term safety profile before it can be developed.